It is usually authorised for adults who are overweight with a number of weight-connected circumstances, including higher blood pressure level or Kind 2 diabetes (higher blood sugar). In March of 2024, the FDA approved an additional indicator for Wegovy—to lessen the potential risk of cardiovascular Loss of life, heart attack, https://glp-1weightlossmed.com/product/wegovy/